Sheard C E, Double J A, Berenbaum M C
Br J Cancer. 1971 Dec;25(4):838-44. doi: 10.1038/bjc.1971.97.
The rat Walker 256 tumour was grown in mice that had previously been thymectomized and treated with anti-lymphocyte serum. These rat tumour-bearing mice were used to determine the therapeutic indices of 4 anti-tumour drugs.The agent with the highest index of the four examined was 5-aziridino 2,4-dinitrobenzamide (CB1954), followed by melphalan, aniline mustard and methotrexate, in that order. This rank order is the same as that found when therapeutic indices are determined on the Walker tumour growing in the rat. In this system, therefore, drugs have been ranked correctly in effectiveness against a rat tumour by measuring their effects on the tumour when growing in an immunosuppressed xenogeneic species. The implications for testing the drug sensitivity of individual human tumours before treating the patient are discussed.
将大鼠沃克256肿瘤接种于先前已接受胸腺切除并注射抗淋巴细胞血清治疗的小鼠体内。这些荷瘤小鼠被用于测定4种抗肿瘤药物的治疗指数。在所检测的4种药物中,治疗指数最高的是5-氮杂环丙基-2,4-二硝基苯甲酰胺(CB1954),其次是美法仑、苯胺氮芥和甲氨蝶呤,顺序依次如此。这个排序与在大鼠体内生长的沃克肿瘤测定治疗指数时得到的排序相同。因此,在这个系统中,通过测量药物对生长于免疫抑制异种动物体内肿瘤的作用,已正确地对药物针对大鼠肿瘤的有效性进行了排序。文中还讨论了在治疗患者之前检测个体人类肿瘤药物敏感性的意义。